Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Raises $10.6M in Public Offering

NEW YORK (GenomeWeb News) – Trovagene today announced that underwriters of its public offering have exercised the over-allotment option to purchase 172,500 additional units to raise a total of nearly $10.6 million in gross proceeds.

The underwriters for the offering paid $8 per unit, which was the price in the public offering of 1.15 million units.

On June 14, the holders of the units may elect to separately trade the common stock and warrants comprising the units on the Nasdaq Capital Market under the symbols "TROV" and "TROVW" respectively. The warrants will be exercisable at a price of $5.32 per share upon separation of the units and expires on June 4, 2017.

Trovagen moved to the Nasdaq from OTCQB a few weeks ago.

Units that are not separated will continue being traded on the Nasdaq Capital Market under ticker symbol "TROVU".

Aegis acted as the sole book-running manager for the offering. Summer Street Research Partners and Brean Murray, Carret &Co. were co-managers for the offering.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.